Foslevodopa–foscarbidopa (Produodopa, AbbVie) is indicated for the 'treatment of advanced levodopa-responsive Parkinson's disease with severe motor fluctuations and hyperkinesia or dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results'.
The dosage schedule is available in the summary of product characteristics for foslevodopa–foscarbidopa.
The company has a commercial arrangement. This makes foslevodopa–foscarbidopa available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.